RMCM
GSK icon

Reynders McVeigh Capital Management’s GSK GSK Stock Holding History

Reynders McVeigh Capital Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,424
Closed -$299K – 237
2021
Q4 		$299K Buy
+5,424
New +$282K 0.02% 197
2020
Q4 		– Sell
-5,599
Closed -$263K – 230
2020
Q3 		$263K Sell
5,599
-7,029
-56% -$352K 0.02% 192
2020
Q2 		$644K Buy
+12,628
New +$648K 0.06% 124
2018
Q1 		– Sell
-6,967
Closed -$309K – 204
2017
Q4 		$309K Sell
6,967
-3,000
-30% -$139K 0.04% 170
2017
Q3 		$506K Sell
9,967
-320
-3% -$16.2K 0.07% 136
2017
Q2 		$554K Buy
10,287
+40
+0.4% +$2.13K 0.07% 129
2017
Q1 		$540K Sell
10,247
-160
-2% -$8.12K 0.07% 137
2016
Q4 		$501K Sell
10,407
-1,391
-12% -$68.7K 0.07% 139
2016
Q3 		$636K Sell
11,798
-899
-7% -$49.3K 0.09% 123
2016
Q2 		$688K Sell
12,697
-2,549
-17% -$134K 0.1% 121
2016
Q1 		$773K Sell
15,246
-1,925
-11% -$95.9K 0.11% 111
2015
Q4 		$866K Sell
17,171
-3,892
-18% -$198K 0.14% 92
2015
Q3 		$1.01M Sell
21,063
-4,559
-18% -$237K 0.18% 86
2015
Q2 		$1.33M Sell
25,622
-8,222
-24% -$463K 0.22% 74
2015
Q1 		$1.95M Sell
33,844
-28,222
-45% -$1.62M 0.34% 47
2014
Q4 		$3.32M Sell
62,066
-174,828
-74% -$9.78M 0.58% 40
2014
Q3 		$13.6M Buy
236,894
+42,872
+22% +$2.63M 2.59% 12
2014
Q2 		$13M Buy
194,022
+12
+0% +$812 2.95% 8
2014
Q1 		$13M Buy
194,010
+6,304
+3% +$426K 3.07% 8
2013
Q4 		$12.5M Buy
187,706
+8,228
+5% +$534K 3.1% 8
2013
Q3 		$11.3M Buy
179,478
+9,250
+5% +$595K 3.12% 8
2013
Q2 		$10.6M Buy
+170,228
New +$10.8M 3.15% 7

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Reynders McVeigh Capital Management's GSK Position: Q1 2022 in Review

Reynders McVeigh Capital Management sold out of GSK (GSK) in Q1 2022, closing a stake of 5,424 shares — an estimated $299K sold.

Reynders McVeigh Capital Management first reported a position in GSK in Q2 2013 and held it in 22 quarters. The position peaked at $13.6M in Q3 2014. 930 funds tracked by Wall St. Rank hold GSK as of Q1 2022.

  • Reynders McVeigh Capital Management reported no remaining GSK position as of Q1 2022 after selling out during the quarter.
  • Reynders McVeigh Capital Management sold 5,424 GSK shares in Q1 2022, an estimated $299K.
  • Reynders McVeigh Capital Management first reported a position in GSK in Q2 2013 and held it in 22 quarters.
  • Reynders McVeigh Capital Management's GSK position peaked at $13.6M in Q3 2014.
  • 930 funds tracked by Wall St. Rank held GSK as of Q1 2022.

Based on Reynders McVeigh Capital Management's 13F filing for Q1 2022, filed 11 May 2022.